Secondary Hyperparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Secondary hyperparathyroidism occurs when the parathyroid glands in the neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints, and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

The Secondary Hyperparathyroidism drugs in development market research report provide comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects.

Key Targets in the Secondary Hyperparathyroidism Pipeline Products Market

The key targets in the Secondary Hyperparathyroidism pipeline products market are Calcium Sensing Receptor, Vitamin D Receptor, Extracellular Calcium Sensing Receptor, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1.

Secondary Hyperparathyroidism Pipeline Products Analysis Market by Targets

Secondary Hyperparathyroidism Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Secondary Hyperparathyroidism Pipeline Products Market

The key mechanisms of action in the Secondary Hyperparathyroidism pipeline products market are Calcium Sensing Receptor Agonist, Vitamin D Receptor Agonist, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D Inhibitor, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1 Inhibitor.

Secondary Hyperparathyroidism Pipeline Products Market Analysis by Mechanism of Actions

Secondary Hyperparathyroidism Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Secondary Hyperparathyroidism Pipeline Products Market

The key routes of administration in the Secondary Hyperparathyroidism pipeline products market are oral, intravenous, parenteral, and transdermal.

Secondary Hyperparathyroidism Pipeline Products Market Analysis by Routes of Administration

Secondary Hyperparathyroidism Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Secondary Hyperparathyroidism Pipeline Products Market

The key molecule types in the Secondary Hyperparathyroidism pipeline products market are small molecule, peptide, and synthetic peptide.

Secondary Hyperparathyroidism Pipeline Products Market Analysis by Molecule Type

Secondary Hyperparathyroidism Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Secondary Hyperparathyroidism Pipeline Products Market

The major companies in the Secondary Hyperparathyroidism pipeline products market are OPKO Health Inc, Shaanxi Micot Technology Co Ltd, Amgen Inc, Cinkate Corp, Jiangsu Hengrui Medicine Co Ltd, Mitsubishi Tanabe Pharma Corp, Novadiol Inc, Scohia Pharma Inc, TaiRx Inc, and Vidasym Inc.

Secondary Hyperparathyroidism Pipeline Products Market Analysis by Companies

Secondary Hyperparathyroidism Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Calcium Sensing Receptor, Vitamin D Receptor, Extracellular Calcium Sensing Receptor, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1
Key mechanism of action Calcium Sensing Receptor Agonist, Vitamin D Receptor Agonist, 1,25-Dihydroxyvitamin D3 24-Hydroxylase Mitochondrial Cytochrome P450 24A1 or Cytochrome P450 CC24 or Vitamin D Inhibitor, and Inositol Hexakisphosphate and Diphosphoinositol Pentakisphosphate Kinase 1 Inhibitor
Key routes of administration Oral, Intravenous, Parenteral, and Transdermal
Key molecule type Small Molecule, Peptide, and Synthetic Peptide
Major companies OPKO Health Inc, Shaanxi Micot Technology Co Ltd, Amgen Inc, Cinkate Corp, Jiangsu Hengrui Medicine Co Ltd, Mitsubishi Tanabe Pharma Corp, Novadiol Inc, Scohia Pharma Inc, TaiRx Inc, and Vidasym Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Amgen Inc
Cinkate Corp
Jiangsu Hengrui Medicine Co Ltd
Mitsubishi Tanabe Pharma Corp
Novadiol Inc
OPKO Health Inc
Scohia Pharma Inc
Shaanxi Micot Technology Co Ltd
TaiRx Inc
Vidasym Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Secondary Hyperparathyroidism – Overview

Secondary Hyperparathyroidism – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Secondary Hyperparathyroidism – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Secondary Hyperparathyroidism – Companies Involved in Therapeutics Development

Amgen Inc

Cinkate Corp

Jiangsu Hengrui Medicine Co Ltd

Mitsubishi Tanabe Pharma Corp

Novadiol Inc

OPKO Health Inc

Scohia Pharma Inc

Shaanxi Micot Technology Co Ltd

TaiRx Inc

Vidasym Inc

Secondary Hyperparathyroidism – Drug Profiles

calcifediol ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

cinacalcet – Drug Profile

Product Description

Mechanism Of Action

CK-15 – Drug Profile

Product Description

Mechanism Of Action

CTA-091 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Dendocrin – Drug Profile

Product Description

Mechanism Of Action

etelcalcetide hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

evocalcet – Drug Profile

Product Description

Mechanism Of Action

History of Events

MT-1013 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SCO-006 – Drug Profile

Product Description

Mechanism Of Action

SHR-6508 – Drug Profile

Product Description

Mechanism Of Action

VS-105 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Secondary Hyperparathyroidism – Dormant Projects

Secondary Hyperparathyroidism – Discontinued Products

Secondary Hyperparathyroidism – Product Development Milestones

Featured News & Press Releases

Jul 06, 2021: MICOT’s MT1013 project completed the enrollment of the first subject in Phase I clinical trials in the United States

Apr 09, 2021: MICOT’s third variety MT1013 was approved for clinical use in the United States

Dec 21, 2020: Launch of Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent in Japan

Jun 29, 2020: ONO receives manufacturing and marketing approval in Japan for Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent

Mar 25, 2020: OPKO Health reports interim results for two ongoing RAYALDEE studies

Sep 04, 2018: OPKO initiates RAYALDEE phase 2 trial in dialysis patients

Jul 16, 2018: OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada

May 22, 2018: Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan

Mar 23, 2018: Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan

Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology

Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD

Jun 05, 2017: OPKO Health Provides Commercial Update for RAYALDEE

Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in Japan

Feb 15, 2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis

Feb 07, 2017: OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Secondary Hyperparathyroidism, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Secondary Hyperparathyroidism – Pipeline by Amgen Inc, 2022

Secondary Hyperparathyroidism – Pipeline by Cinkate Corp, 2022

Secondary Hyperparathyroidism – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Secondary Hyperparathyroidism – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022

Secondary Hyperparathyroidism – Pipeline by Novadiol Inc, 2022

Secondary Hyperparathyroidism – Pipeline by OPKO Health Inc, 2022

Secondary Hyperparathyroidism – Pipeline by Scohia Pharma Inc, 2022

Secondary Hyperparathyroidism – Pipeline by Shaanxi Micot Technology Co Ltd, 2022

Secondary Hyperparathyroidism – Pipeline by TaiRx Inc, 2022

Secondary Hyperparathyroidism – Pipeline by Vidasym Inc, 2022

Secondary Hyperparathyroidism – Dormant Projects, 2022

Secondary Hyperparathyroidism – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Secondary Hyperparathyroidism, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Secondary Hyperparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Secondary Hyperparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Secondary Hyperparathyroidism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.